Peptides A–Z
Everything you need to know about peptides — scientifically contextualised.
Identity, mechanism, evidence base, legal status, risks, comparisons — per peptide in one entry. With visible evidence tier and sources under every statement. Not a usage recommendation.
35
Peptides recorded
136
Studies aggregated
12
Countries with legal status
Evidence distribution
113 observations
Newsletter
Stay current
New peptides, new studies, new context — monthly, free. No sales, unsubscribe anytime.
What you'll find
Six ways into the peptide world
01
Identity
Profiles per peptide
Chemical identity, class, synonyms, sequence, molecular weight — compact at the top of every entry.
02
Mechanism
How it acts biologically
Neutrally explained mechanism of action, glossary terms auto-linked.
03
Studies
Evidence transparent
Every claim with a visible evidence tier — human RCT to anecdotal. Filterable.
04
Legal status
Country by country
Approved, research, restriction, ban — with source and date.
05
Comparison
Two peptides side by side
Identity, evidence, legal status, adverse events — directly comparable.
06
Glossary
Technical terms, plainly
Hover a term and the definition appears in-text.
Evidence distribution
What this platform documents
Aggregated across all catalogued peptides. Every documented observation carries its visible evidence tier — from human RCT down to anecdotal. Weaker tiers are deliberately visible.
113 documented observations total
Human RCT44
38.9% · Only Human RCT in the lexicon →
Human trial30
26.5% · Only Human trial in the lexicon →
Animal model18
15.9% · Only Animal model in the lexicon →
In vitro11
9.7% · Only In vitro in the lexicon →
Preclinical2
1.8% · Only Preclinical in the lexicon →
Anecdotal4
3.5% · Only Anecdotal in the lexicon →
Theoretical4
3.5% · Only Theoretical in the lexicon →
Updates
Recently reviewed
The five most recently updated peptide entries. Full history in the RSS feed.
Families
By application area
In focus
Human RCTResearch other · 5 studies
Bremelanotide
Synthetic cyclic heptapeptide acting as a non-selective melanocortin-receptor agonist. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women..
Open entry →Quick facts
CAS189691-06-3
SequenceAc-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH
MW1025.18 g/mol
t½2.7 h
Effects3
Conflicts0
Entry register
All catalogued peptides
AOD-9604
Human RCTGrowth · 1815.09 g/mol · t½ 0.4h
Synthetic 16-amino-acid peptide corresponding to the C-terminal fragment of human growth hormone (hGH 176-191). Originally developed by Meta…
Argireline
Human trialCosmetic · 888.99 g/mol
Synthetic hexapeptide marketed as a topical anti-wrinkle ingredient (e.g. by Lipotec/Lubrizol). Mechanism modelled on the SNAP-25-blocking a…
BPC-157
Animal modelHealing · 1419.5 g/mol · t½ 4h
Synthetic pentadecapeptide (15 amino acids) derived from a sequence of a gastric-juice protein. Studied predominantly in animal models on he…
Bremelanotide
Human RCTResearch other · 1025.18 g/mol · t½ 2.7h
Synthetic cyclic heptapeptide acting as a non-selective melanocortin-receptor agonist. FDA-approved in 2019 as Vyleesi for hypoactive sexual…
Cagrilintide
Human RCTMetabolic · 4253.7 g/mol · t½ 168h
Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabe…
CJC-1295
Human trialGrowth · 3647.3 g/mol · t½ 144h
Long-acting synthetic GHRH analogue modified for albumin binding (DAC). Stimulates endogenous growth-hormone release. Pharmacodynamic effect…
DSIP
Human trialResearch other · 848.81 g/mol · t½ 0.1h
Synthetic nonapeptide isolated in 1977 by Guido Monnier and Marcel Schoenenberger from the blood of rabbits in delta sleep. Despite the name…
Dulaglutide
Human RCTMetabolic · 59670 g/mol · t½ 110h
GLP-1 receptor agonist designed as a fusion protein of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc fragment. FDA…
Epitalon
Human trialResearch other · 390.35 g/mol · t½ 0.3h
Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal extract epithalamin (V. Khavinson, St. Petersburg). Investigated in the Rus…
Exenatide
Human RCTMetabolic · 4186.6 g/mol · t½ 2.4h
Synthetic version of exendin-4, originally isolated from the saliva of the Gila monster (Heloderma suspectum). First GLP-1 receptor agonist,…
FOXO4-DRI
Animal modelResearch other · 3735 g/mol · t½ 0.5h
Synthetic peptide with D-Retro-Inverso structure (all amino acids as D-form, sequence reversed), developed in 2017 as an experimental senoly…
GHK-Cu
Human trialCosmetic · 340.4 g/mol
Endogenous tripeptide (glycyl-L-histidyl-L-lysine) that chelates copper(II) ions. Studied in skin models and small human trials on collagen …
GHRP-2
Human trialGrowth · 817.93 g/mol · t½ 0.5h
Synthetic hexapeptide of the GH secretagogue family. Approved in Japan as GHRP Kaken as a diagnostic test for GH deficiency. Not available a…
GHRP-6
Human trialGrowth · 873.02 g/mol · t½ 0.4h
Synthetic hexapeptide that founded the class of growth-hormone-releasing peptides (GHRPs). Cyril Bowers identified GHRP-6 in the late 1970s …
Hexarelin
Human trialGrowth · 887.05 g/mol · t½ 0.9h
Synthetic hexapeptide of the growth-hormone secretagogue (GHRP) family. In the 1990s investigated as an acromegaly diagnostic and for GH def…
Ipamorelin
Human RCTGrowth · 711.86 g/mol · t½ 2h
Synthetic pentapeptide and selective growth-hormone secretagogue. Developed at Novo Nordisk in the 1990s as a pentapeptide GHRP successor; c…
Liraglutide
Human RCTMetabolic · 3751 g/mol · t½ 13h
GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 dia…
Lixisenatide
Human RCTMetabolic · 4858.5 g/mol · t½ 3h
Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyx…
Matrixyl
Human RCTCosmetic · 802.06 g/mol
Synthetic pentapeptide (KTTKS) with a palmitoyl modification, marketed as a topical anti-aging ingredient (Lipotec/Sederma). Structurally de…
Melanotan II
Human trialResearch other · 1024.18 g/mol · t½ 1h
Cyclic hepta-peptide and non-selective melanocortin-receptor agonist. Originally researched at the University of Arizona as a sun-protection…
MGF (Mechano Growth Factor)
Animal modelGrowth · 2867.2 g/mol · t½ 0.1h
Synthetic peptide corresponding to the C-terminal E-domain of the IGF-1 splice variant IGF-1Ec. Described in preclinical studies as a 'mecha…
Octreotide
Human RCTResearch other · 1019.24 g/mol · t½ 1.7h
Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for ac…
Retatrutide
Human RCTMetabolic · 4731.6 g/mol · t½ 144h
Synthetic triagonist peptide that simultaneously activates the GLP-1, GIP and glucagon receptors. Developed by Eli Lilly; in phase-3 trials …
Selank
Human trialResearch other · 751.85 g/mol · t½ 0.3h
Synthetic heptapeptide derived from natural tuftsin. Approved as an anxiolytic (Selank) in Russia and some CIS states. Western phase-3 trial…
Semaglutid
Human RCTMetabolic · 4113.6 g/mol · t½ 165h
Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wego…
Semax
Human trialResearch other · 813.92 g/mol · t½ 0.3h
Synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10). Approved in Russia for ischaemic str…
Sermorelin
Human RCTGrowth · 3358 g/mol · t½ 0.2h
Synthetic analogue of the first 29 amino acids of human GHRH. Stimulates pulsatile growth-hormone secretion from the pituitary. Formerly FDA…
SNAP-8
Human trialCosmetic · 1075.16 g/mol
Synthetic octapeptide marketed as a topical anti-wrinkle ingredient (Centerchem/Lipotec). Structurally related to Argireline (Acetyl Hexapep…
Survodutide
Human RCTMetabolic · 4727 g/mol · t½ 168h
Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in p…
TB-500
Animal modelHealing · 888 g/mol
Synthetic fragment of the endogenous protein Thymosin Beta-4, specifically the actin-binding sequence. Preclinical models investigate effect…
Tesamorelin
Human RCTGrowth · 5135.83 g/mol · t½ 0.4h
Stabilised GHRH analog (growth-hormone-releasing hormone). FDA-approved in 2010 as Egrifta for reduction of abdominal lipohypertrophy in HIV…
Thymalin
Human trialHealing · 1000 g/mol · t½ 0.5h
Complex of low-molecular polypeptides extracted from calf thymus. Approved in Russia since the 1970s as an immunomodulator. The exact compos…
Thymosin Alpha-1
Human RCTHealing · 3108.32 g/mol · t½ 2h
Synthetic 28-amino-acid peptide identical to a naturally occurring thymus peptide. Approved as Zadaxin in more than 30 countries (not US/EU)…
Tirzepatide
Human RCTMetabolic · 4813 g/mol · t½ 116h
Synthetic peptide that simultaneously activates the GLP-1 and GIP receptor (dual agonist). Approved in the US and EU for type 2 diabetes (Mo…
Triptorelin
Human RCTResearch other · 1311.45 g/mol · t½ 3h
Synthetic decapeptide GnRH agonist with increased affinity over native gonadotropin-releasing hormone. FDA- and EMA-approved since the 1980s…
Method
How we work
We aggregate data from PubMed, Europe PMC, PubChem and regulatory publications. Every summary is written in our own words, with our own synthesis — no copied text. Before each build, a compliance guard scans content against a list of forbidden phrases.
Full method →PubMed / Europe PMC
Study aggregation
PubChem / ChEMBL
Chemical identifiers
FDA / EMA / TGA
Country-specific legal status
Our words. Our synthesis.
No copied content.